
Laura Gesualdi
Articles
-
Jul 16, 2023 |
survivornet.com | Laura Gesualdi |Elizabeth Comen |Muneeb Z. Niazi |James Taylor
The American Society of Clinical Oncology (ASCO) has issued a new recommendation that some women with advanced breast cancer be tested for a mutation in the ESR1 gene. The recommendation comes after the approval of a drug called elacestrant (Orserdu) earlier this year. The drug showed promise in treating people whose tumors were ER-positive, HER2-negative, had the ESR1 mutation, and had continued to grow after hormone therapy.
-
Jul 16, 2023 |
survivornet.com | Laura Gesualdi |Elizabeth Comen |Muneeb Z. Niazi |James Taylor
ASCO Issues New Recommendation for ESR1 TestingThe American Society of Clinical Oncology (ASCO) has issued a new recommendation that some women with advanced breast cancer be tested for a mutation in the ESR1 gene. The recommendation comes after the approval of a drug called elacestrant (Orserdu) earlier this year. The drug showed promise in treating people whose tumors were ER-positive, HER2-negative, had the ESR1 mutation, and had continued to grow after hormone therapy.
-
Jul 11, 2023 |
survivornet.com | Laura Gesualdi
Are There New Developments for Treating Esophageal Cancer? Over the past decade, rates of esophageal cancer have been increasing slightly. Unfortunately, the disease can be difficult to treat because it is often diagnosed at later stages. It’s important to be aware of symptoms, such as pain/difficulty swallowing, weight loss, pain behind the breastbone, and hoarseness and/or a cough.
-
Jun 19, 2023 |
survivornet.com | Laura Gesualdi
Empowering patients to make the best treatment decisions is a crucial part of cancer care — and recent developments are aiming to do just that. Prasanth Reddy, Senior Vice President, Global Enterprise Head of Oncology at LabCorp, recently sat down with SurvivorNet to discuss how diagnostic tests, such as genetic sequencing and molecular profiling, are becoming a critical part of making treatment decisions.
-
Jun 14, 2023 |
survivornet.com | Laura Gesualdi
For most people who work in and around oncology, they come at cancer research and drug development from an outside standpoint. However, for one of the top doctors working in cell therapy, Dr. Rosanna Ricafort, Vice President of Cell Therapy Clinical Development at Bristol Myers Squibb, it’s deeply personal — as she herself is living with non-Hodgkin’s lymphoma.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →